AnaptysBio Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
AnaptysBio Inc (ANAB)
AnaptysBio Inc stock price live, this page displays NASDAQ ANAB stock exchange data. View the ANAB premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the AnaptysBio Inc real time stock price chart below.
What Is the AnaptysBio Inc Stock Price Today?
The AnaptysBio Inc stock price today is 20.33.
What Is the Stock Symbol for AnaptysBio Inc?
The stock symbol for AnaptysBio Inc is ""ANAB.""
What Stock Exchange Does AnaptysBio Inc Trade On?
AnaptysBio Inc is listed and trades on the NASDAQ stock exchange.
Is AnaptysBio Inc a Good Stock to Buy?
Determining whether AnaptysBio Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ANAB quote. (ISIN: US0327241065)
What Is the AnaptysBio Inc Stock Price Today?
The AnaptysBio Inc stock price today is 20.33.
What Is the Stock Symbol for AnaptysBio Inc?
The stock symbol for AnaptysBio Inc is ""ANAB.""
What Stock Exchange Does AnaptysBio Inc Trade On?
AnaptysBio Inc is listed and trades on the NASDAQ stock exchange.
Is AnaptysBio Inc a Good Stock to Buy?
Determining whether AnaptysBio Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ANAB quote. (ISIN: US0327241065)
20.33
-0.07(-0.34%)
Real-time Data·
Fair Value
An estimate of a AnaptysBio's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
20.29
20.81
52 wk Range
12.21
40.70
ANAB Scorecard
Full Analysis
Quickly burning through cash
ANAB is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a AnaptysBio's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
20.2920.81
52 wk Range
12.2140.70
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ANAB Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a AnaptysBio's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
45.50
Upside
+123.81%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
- AnaptysBio Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- AnaptysBio Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - AnaptysBio Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Anaptysbio director Fenton sells $72k in stock
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
AnaptysBio Inc Company Profile
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Compare ANAB to Peers and Sector
Metrics to compare | ANAB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipANABPeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.3x | −1.2x | −0.6x | |
PEG Ratio | −0.15 | −0.05 | 0.00 | |
Price/Book | −12.8x | 1.7x | 2.6x | |
Price / LTM Sales | 4.7x | 8.4x | 3.3x | |
Upside (Analyst Target) | 135.3% | 268.1% | 38.7% | |
Fair Value Upside | Unlock | 23.1% | 5.1% | Unlock |
Analyst Ratings
9 Buy
2 Hold
0 Sell
Ratings:
11 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 45.50
(+123.81% Upside)
Earnings
Latest Release
Aug 07, 2025
EPS / Forecast
-1.34 / -1.52
Revenue / Forecast
22.26M / 11.51M
People Also Watch
FAQ
What Stock Exchange Does AnaptysBio Trade On?
AnaptysBio is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for AnaptysBio?
The stock symbol for AnaptysBio is "ANAB."
What Is the AnaptysBio Market Cap?
As of today, AnaptysBio market cap is 570.30M.
What Is AnaptysBio's Earnings Per Share (TTM)?
The AnaptysBio EPS (TTM) is -4.46.
When Is the Next AnaptysBio Earnings Date?
AnaptysBio will release its next earnings report on 10 Nov 2025.
From a Technical Analysis Perspective, Is ANAB a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has AnaptysBio Stock Split?
AnaptysBio has split 0 times.
How Many Employees Does AnaptysBio Have?
AnaptysBio has 136 employees.
What is the current trading status of AnaptysBio (ANAB)?
As of 28 Aug 2025, AnaptysBio (ANAB) is trading at a price of 20.33, with a previous close of 20.40. The stock has fluctuated within a day range of 20.29 to 20.81, while its 52-week range spans from 12.21 to 40.70.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.